User contributions
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
- 20:47, 22 January 2020 (diff | hist) . . (+116) . . N User talk:Jwarner (Created page with "The page you'd need to edit for the banner is: https://hemonc.org/w/index.php?title=MediaWiki:Sitenotice&action=edit") (current)
- 17:41, 22 January 2020 (diff | hist) . . (+2,732) . . m Chronic lymphocytic leukemia (current)
- 16:42, 22 January 2020 (diff | hist) . . (-1) . . m Hepatocellular carcinoma (→Regimen {{#subobject:f3a095|Variant=1}}) (current)
- 16:41, 22 January 2020 (diff | hist) . . (+346) . . m HemOnc vocabulary concepts (→Study-level concepts) (current)
- 16:36, 22 January 2020 (diff | hist) . . (+474) . . m HemOnc vocabulary concepts (→Component-level concepts)
- 13:55, 22 January 2020 (diff | hist) . . (+345) . . m HemOnc vocabulary concepts (→Regimen-level concepts)
- 13:30, 22 January 2020 (diff | hist) . . (+316) . . m HemOnc vocabulary concepts (→Condition-level concepts)
- 13:23, 22 January 2020 (diff | hist) . . (+37) . . m HemOnc vocabulary concepts
- 13:21, 22 January 2020 (diff | hist) . . (+518) . . m HemOnc vocabulary concepts
- 12:45, 22 January 2020 (diff | hist) . . (+85) . . m Regimen classes (→Trastuzumab-based regimen) (current)
- 12:44, 22 January 2020 (diff | hist) . . (+33) . . m Regimen classes (→Endocrine-based regimen)
- 12:24, 22 January 2020 (diff | hist) . . (+2,208) . . m Myelodysplastic syndrome (current)
- 12:17, 22 January 2020 (diff | hist) . . (+2,646) . . m Myelodysplastic syndrome (→Luspatercept monotherapy {{#subobject:8dgac1|Regimen=1}})
- 12:17, 22 January 2020 (diff | hist) . . (-2,621) . . m Myelodysplastic syndrome (→Placebo)
- 12:16, 22 January 2020 (diff | hist) . . (+2,994) . . m Myelodysplastic syndrome (→Erythropoietin monotherapy {{#subobject:9uyac1|Regimen=1}})
- 12:15, 22 January 2020 (diff | hist) . . (-2,949) . . m Myelodysplastic syndrome (→Epoetin & Lenalidomide {{#subobject:495acc|Regimen=1}})
- 12:15, 22 January 2020 (diff | hist) . . (+7,531) . . m Myelodysplastic syndrome (→Luspatercept monotherapy {{#subobject:8dgac1|Regimen=1}})
- 12:14, 22 January 2020 (diff | hist) . . (-7,531) . . m Myelodysplastic syndrome (→Lenalidomide monotherapy {{#subobject:dfbcc0|Regimen=1}})
- 12:13, 22 January 2020 (diff | hist) . . (+1,476) . . Myelodysplastic syndrome
- 12:07, 22 January 2020 (diff | hist) . . (+211) . . m Myelodysplastic syndrome (→Guidelines)
- 12:06, 22 January 2020 (diff | hist) . . (+80) . . m Myelodysplastic syndrome (→"How I treat")
- 12:02, 22 January 2020 (diff | hist) . . (+1,759) . . Myelodysplastic syndrome (→First-line therapy)
- 11:55, 22 January 2020 (diff | hist) . . (+1,095) . . N Luspatercept (Reblozyl) (Created page with "==Mechanism of action== From the NCI Drug Dictionary: A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor t...") (current)
- 11:53, 22 January 2020 (diff | hist) . . (+75) . . m Epoetin alfa (Procrit) (→References) (current)
- 11:31, 22 January 2020 (diff | hist) . . (+4) . . m Drug index (→L) (current)
- 22:13, 21 January 2020 (diff | hist) . . (+849) . . m Follicular lymphoma (current)
- 19:58, 21 January 2020 (diff | hist) . . (+14) . . m Prostate cancer (current)
- 19:56, 21 January 2020 (diff | hist) . . (+4,094) . . m Prostate cancer
- 19:45, 21 January 2020 (diff | hist) . . (+8) . . m Esophageal cancer (→Fluorouracil, Paclitaxel, RT {{#subobject:52e768|Regimen=1}}) (current)
- 16:58, 21 January 2020 (diff | hist) . . (-12) . . m Prostate cancer - historical (→Castration) (current)
- 16:53, 21 January 2020 (diff | hist) . . (+13) . . m Ontology (current)
- 15:44, 21 January 2020 (diff | hist) . . (+1,352) . . m Prostate cancer (→Cabazitaxel & Prednisone {{#subobject:23 |Regimen=1}})
- 21:46, 20 January 2020 (diff | hist) . . (+501) . . m Hepatocellular carcinoma
- 21:38, 20 January 2020 (diff | hist) . . (+1,485) . . m Hepatocellular carcinoma (→First-line therapy for advanced or metastatic disease)
- 21:14, 20 January 2020 (diff | hist) . . (-23) . . m T-cell prolymphocytic leukemia (current)
- 22:26, 18 January 2020 (diff | hist) . . (+2,765) . . m Ovarian cancer (current)
- 21:54, 18 January 2020 (diff | hist) . . (+26) . . m Renal cell carcinoma (→Regimen {{#subobject:9d436d|Variant=1}}) (current)
- 21:52, 18 January 2020 (diff | hist) . . (+3,605) . . m Renal cell carcinoma
- 21:09, 18 January 2020 (diff | hist) . . (+729) . . m Editing test page (→BEACOPP 4+4) (current)
- 17:52, 18 January 2020 (diff | hist) . . (+1,620) . . m Multiple myeloma, relapsed-refractory (current)
- 21:47, 17 January 2020 (diff | hist) . . (+2,169) . . m Non-small cell lung cancer, EGFR-mutated (→Advanced or metastatic disease, EGFR inhibitor-naive) (current)
- 21:40, 17 January 2020 (diff | hist) . . (+2,479) . . Non-small cell lung cancer, EGFR-mutated (→Gefitinib monotherapy {{#subobject:fb3998|Regimen=1}})
- 14:01, 17 January 2020 (diff | hist) . . (+154) . . m Esophageal cancer (→Definitive therapy)
- 13:58, 17 January 2020 (diff | hist) . . (-28) . . m Esophageal cancer (→Fluorouracil & Paclitaxel {{#subobject:58ub68|Regimen=1}})
- 13:58, 17 January 2020 (diff | hist) . . (+1,818) . . Esophageal cancer (→Consolidation after definitive therapy)
- 13:54, 17 January 2020 (diff | hist) . . (+88) . . m Esophageal cancer (→Fluorouracil, Paclitaxel, RT {{#subobject:52e768|Regimen=1}})
- 13:53, 17 January 2020 (diff | hist) . . (-152) . . m Esophageal cancer (→Fluorouracil, Paclitaxel, RT {{#subobject:52e768|Regimen=1}})
- 13:48, 17 January 2020 (diff | hist) . . (+11) . . m Esophageal cancer (→Nivolumab monotherapy {{#subobject:10ee99|Regimen=1}})
- 15:57, 16 January 2020 (diff | hist) . . (+146) . . m Non-small cell lung cancer (current)
- 15:56, 16 January 2020 (diff | hist) . . (+776) . . m Non-small cell lung cancer - historical (current)
(newest | oldest) View (newer 50 | older 50) (20 | 50 | 100 | 250 | 500)
